Literature DB >> 19129079

Tigecycline for treatment of nosocomial-acquired pneumonia possibly caused by multi-drug resistant strains of Stenotrophomonas maltophilia.

D Blanquer1, J De Otero, E Padilla, F Gómez, A Mayol, R Irigaray, P Espejo, M A Rada, G Makrantoni, A R Pérez.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19129079     DOI： 10.1179/joc.2008.20.6.761

Source DB:  PubMed          Journal:  J Chemother        ISSN： 1120-009X            Impact factor:   1.714


× No keyword cloud information.
  3 in total

1.  Stenotrophomonas maltophilia infections in a general hospital: patient characteristics, antimicrobial susceptibility, and treatment outcome.

Authors:  George Samonis; Drosos E Karageorgopoulos; Sofia Maraki; Panagiotis Levis; Dimitra Dimopoulou; Nikolaos A Spernovasilis; Diamantis P Kofteridis; Matthew E Falagas
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

2.  Potential role of tigecycline in the treatment of community-acquired bacterial pneumonia.

Authors:  Mary L Townsend; Melanie W Pound; Richard H Drew
Journal:  Infect Drug Resist       Date:  2011-03-02       Impact factor: 4.003

3.  Antimicrobial susceptibility of stenotrophomonas maltophilia isolates from Korea, and the activity of antimicrobial combinations against the isolates.

Authors:  Hae-Sun Chung; Seong Geun Hong; Young Ree Kim; Kyeong Seob Shin; Dong Hee Whang; Jee Young Ahn; Yeon-Joon Park; Young Uh; Chulhun L Chang; Jong Hee Shin; Hye Soo Lee; Kyungwon Lee; Yunsop Chong
Journal:  J Korean Med Sci       Date:  2013-01-08       Impact factor: 2.153
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.